Navigation Links
Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Date:12/10/2007

regression was used to compare the likelihood of readmission within 30 and 90 days.

The analysis included 38,664 patient discharges with 53 percent (20,577) receiving LMWH and 47 percent (18,087) receiving UFH. Among patients who received LMWH, 97.3 percent (20,021) of them received Lovenox, with the remaining 2.7% receiving other LMWHs. The two groups were similar in clinical and demographic characteristics. The average length of hospital stay for the UFH group was 1.1 days longer (5.7 days vs. 4.6) days. After adjustment for covariates, the average total direct hospital costs were $3,618 for UFH and $3,068 for LMWH (difference $550, P<0.0001). Lovenox was associated with reduced cost in most categories although anticoagulation therapy costs were higher for LMWH ($242 versus $41 for UFH, P<0.0001). LMWH was associated with lower rates of VTE-related readmission at both 30 days (11.2% vs 12.1%; odds ratio [OR] 0.89, 95% confidence interval [CI] 0.84-0.96; P=0.001) and 90 days (13.1% vs 13.8%; OR 0.91, 95% CI 0.85-0.96; P<0.001).

Dr. Geno Merli, Director at the Jefferson Center for Vascular Disease, Jefferson Medical College, Philadelphia, PA and a lead investigator of the analysis said, "What the results showed is that despite higher drug-related costs for Lovenox, the total direct medical costs for the treatment of VTE is reduced when compared to using UFH. For every 1,000 patients treated for documented DVT, the use of Lovenox may save approximately half a million dollars."

About Premier's Perspective(TM) Database

Premier's Perspective(TM) database is the most comprehensive clinical, financial and operational comparative database in the U.S. and contains information from hundreds of hospitals and millions of discharges, providing means by which hospitals can benchmark their efforts against other hospitals in an effort to improve quality and reduce costs.

About Venous Thromboembolism (VTE)

Venous thromboembolism is a gener
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the Morgan Stanley Global Healthcare ... , Presentation date: Tuesday September 9, 2014 , Presentation ... webcast and 30-day archive of this presentation will be available ... Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company ...
(Date:9/2/2014)... N.C. , Sept. 2, 2014  Edison ... announced a partnership with the American Association for ... association of respiratory care specialists. Edison Nation Medical, ... and small business to commercialize their innovation ideas, ... association,s community of more than 50,000 respiratory therapists ...
(Date:9/2/2014)... September 2, 2014 Today, Analysts ... WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted on ...
Breaking Medicine Technology:Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
(Date:9/3/2014)... (PRWEB) September 03, 2014 Job seekers ... for their next position can now do both on ... has created a seamless tool for investigating employment and ... (massively open online courses) are closing skills gaps and ... to traditional degree programs and brick and mortar universities. ...
(Date:9/3/2014)... NJ (PRWEB) September 03, 2014 ... will be offering free screenings for depression on ... Townsquare Mall (Macy’s Court). More than 1,000 organizations ... events including hospitals, colleges and military installations. After ... to local resources and agencies that can offer ...
(Date:9/3/2014)... Joulebody, the NYC based juice and vegan ... detox and weight-loss program in time for post-summer ...     Because it’s good for celiac, diabetics, and anyone looking ...     Because using an elimination diet helps build better energy. ... letting go of caffeine, sugar, and excess meat eating ...
(Date:9/2/2014)... Autumn is well under way and famous ... season with worldwide people. Recently, it has made ... ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, and Bluehost are the ... Since 2002 HostGator has been known as a ... for reliability remains with it today. It is ...
(Date:9/2/2014)... include the sensation of grit in the eye, frequently ... are poorly understood., The researchers base their findings on ... 57) from the TwinsUK cohort, drawn from the registry ... is widely regarded as representative of the UK general ... wide range of diseases and genetic traits over the ...
Breaking Medicine News(10 mins):Health News:iHire Announces Partnership with MOOCtracks 2Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 3Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 4Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... 23 WebMD Health Corp. (Nasdaq: WBMD ) ... that executives of WebMD are scheduled to participate at the ... 25, 2009 at 12:40 p.m. ET. Investors, analysts and ... audio broadcast of the presentation over the Internet. The ...
... On Wednesday, February 25, 2009, the Institute for ... roundtable discussion bringing leading scientists in the field of ... significance (MGUS). The event is being cochaired by James ... at the IMBCR and Robert A. Kyle, MD, who ...
... with Crain,s Cleveland Business, today presented a 2009 NorTech ... development of a Biotech Platform to Detect, Monitor, and ... developed a set of diagnostic tests used by physicians ... by determining drug resistance and disease "strength" of the ...
... #1 FOR IMMEDIATE RELEASE , Egg-irony: High cholesterol food ... Chemistry , Researchers in Canada are reporting evidence that ... may reduce another heart disease risk factor high ... that act like a popular group of prescription medications in ...
... TAMPA, Fla., Feb. 23 /PRNewswire/ -- ... data management solutions company, today announced the release ... cleanses, standardizes and integrates data from multiple platforms. ... businesses encompassing small, mid-size and "Fortune 500" companies, ...
... Sunrise Senior Living, Inc. (NYSE: SRZ ) today ... on Monday, March 2, 2009, at 9 a.m. ET to ... Mark Ordan, chief executive officer, and Richard Nadeau, chief financial ... conference call is 877-795-3638 or 719-325-4841 (from outside the U.S.). ...
Cached Medicine News:Health News:International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease 2Health News:Case Western Reserve University faculty named 2009 NorTech Innovation Award winner 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 3Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 4Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 5Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 6Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 7Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 8Health News:Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed 2Health News:Sunrise to Host Conference Call and Webcast to Discuss Fourth-Quarter and Full-Year 2008 Financial Results 2
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
CRP Liquid Conrtols level 2...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: